Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ACHL
- Price
- -
- Stock movement up
- +0.01 (0.68%)
- Company name
- Achilles Therapeutics PLC ADR
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 60.83M
- Ent value
- -5.69M
- Price/Sales
- -
- Price/Book
- 0.59
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 34.55%
- 3 year return
- -20.81%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-09-12
DIVIDENDS
ACHL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 0.59 |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 41.10M |
| EPS (TTM) | -1.65 |
| FCF per share (TTM) | -1.13 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -2.36M |
| Operating income (TTM) | -72.02M |
| Net income (TTM) | -66.87M |
| EPS (TTM) | -1.65 |
| EPS (1y forward) | -0.12 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 86.05M |
| Net receivables | 21.79M |
| Total current assets | 111.63M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 122.68M |
| Accounts payable | 4.25M |
| Short/Current long term debt | 3.62M |
| Total current liabilities | 18.47M |
| Total liabilities | 19.54M |
| Shareholder's equity | 103.14M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -48.99M |
| Capital expenditures (TTM) | 740.64K |
| Free cash flow (TTM) | -45.81M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -64.84% |
| Return on Assets | -54.51% |
| Return on Invested Capital | -62.64% |
| Cash Return on Invested Capital | -42.91% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| ACHL | S&P500 | |
| Current price drop from All-time high | -91.71% | -7.74% |
| Highest price drop | -96.08% | -56.47% |
| Date of highest drop | 11 Sep 2024 | 9 Mar 2009 |
| Avg drop from high | -83.78% | -10.99% |
| Avg time to new high | 333 days | 12 days |
| Max time to new high | 995 days | 1805 days |
COMPANY DETAILS
Marketcap
60.83M
Marketcap category
Small-cap
Description
Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.
Employees
204
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner